Surmounting Barriers in Non-resectable Recurrent Glioblastoma with a Single Treatment of Bizaxofusp, an Engineered IL-4R Directed Fusion Protein
- Highlight the necessity of combining intratumoral delivery with the multi-pronged MoA to substantially extend survival in non-resectable rGBM patients
- Integrating paired patient biopsies, intratumoral drug distribution, and patient-derived organoid models to interrogate MoA and support clinical observations
- Scrutinize historical survival outcomes in non-resectable rGBM and their implication on applying external control arms in contemporary clinical trial design